The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer an SGLT2 inhibitor formulation as the second layer and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1) and hydrochloric acid salt Pattern P-5 preferably in substantially pure form and other forms as described herein pharmaceutical compositions containing structures of compound I or ...

Described are pharmaceutical compositions for use in the treatment of hepatitis B virus infection or co-infection in an adult human patient for once a day administration comprising from 0.5 mg to 1.0 mg of entecavir adhered to a pharmaceutically acceptable carrier substrate.

The disclosure provides compounds of formula I including Ia Ib Ic or Id including their salts as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system especially affective and neurodegenerative disorders.

A compound of Formula I is set forth including pharmaceutically acceptable salts thereof: wherein Het is a 5 or 6-membered heterocycle with —N —O or —S adjacent to the —Ar substituent or adjacent to the point of attachment for the —Ar substituent; Ar is aryl or heteroaryl; R is —CH3 —CH2F —CHF2 or —CH═CH2; V is —H —CH3 or ═O; W is —NO2 —Cl —Br —CH2OH or —CN; X is —Cl —Br —F...